These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18163518)

  • 21. A case of Raynaud's phenomenon in mixed connective tissue disease responding to rituximab therapy.
    Haroon M; O'Gradaigh D; Foley-Nolan D
    Rheumatology (Oxford); 2007 Apr; 46(4):718-9. PubMed ID: 17289791
    [No Abstract]   [Full Text] [Related]  

  • 22. Rituximab in the treatment of autoimmune haematological disorders.
    Provan D; Newland AC; Amadori S; Stasi R
    Br J Haematol; 2008 Oct; 143(2):294; author reply 295. PubMed ID: 18752592
    [No Abstract]   [Full Text] [Related]  

  • 23. Refractory severe connective tissue disease thrombocytopenia: is rituximab treatment effective and safe?
    Zheng WJ; Zhang X; Wang Q; Xu D; Zeng XF; Zhang FC
    Ann Rheum Dis; 2009 Jun; 68(6):1077-8. PubMed ID: 19435726
    [No Abstract]   [Full Text] [Related]  

  • 24. [Rituximab (Mabthera)--new approach in treatment of rheumatoid arthritis].
    Anić B
    Reumatizam; 2007; 54(2):72-3. PubMed ID: 18351146
    [No Abstract]   [Full Text] [Related]  

  • 25. Rituximab and antineutrophil cytoplasmic antibody-associated vasculitis: granulomatous disease more resistant than vasculitis disease?
    Wong CF
    J Clin Rheumatol; 2008 Apr; 14(2):61-4. PubMed ID: 18391671
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.
    Quartuccio L; Lombardi S; Fabris M; Masolini P; Saracco M; Pellerito R; De Vita S
    Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.
    Levesque MC; St Clair EW
    J Allergy Clin Immunol; 2008 Jan; 121(1):13-21; quiz 22-3. PubMed ID: 18206502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab.
    McGonagle D; Tan AL; Madden J; Rawstron AC; Rehman A; Emery P; Thomas S
    Rheumatology (Oxford); 2008 Apr; 47(4):552-3. PubMed ID: 18281368
    [No Abstract]   [Full Text] [Related]  

  • 29. Comment on: a case of Raynaud's phenomenon in mixed connective tissue disease responding to Rituximab therapy response.
    Dunkley L; Green M; Gough A
    Rheumatology (Oxford); 2007 Oct; 46(10):1628-9. PubMed ID: 17766999
    [No Abstract]   [Full Text] [Related]  

  • 30. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis.
    Hellmann M; Jung N; Owczarczyk K; Hallek M; Rubbert A
    Rheumatology (Oxford); 2008 Jun; 47(6):929-30. PubMed ID: 18411212
    [No Abstract]   [Full Text] [Related]  

  • 31. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement.
    Ross AH; Jaycock P; Cook SD; Dick AD; Tole DM
    Br J Ophthalmol; 2009 Apr; 93(4):421-2, 548. PubMed ID: 19321473
    [No Abstract]   [Full Text] [Related]  

  • 32. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mouse opens door for study of autoimmune diseases.
    Check E
    Nature; 2004 Apr; 428(6985):786. PubMed ID: 15103338
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of relapsing polychondritis with rituximab: a retrospective study of nine patients.
    Leroux G; Costedoat-Chalumeau N; Brihaye B; Cohen-Bittan J; Amoura Z; Haroche J; Limal N; Bletry O; Piette JC
    Arthritis Rheum; 2009 May; 61(5):577-82. PubMed ID: 19405005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attenuated doses of rituximab for the treatment of adults with autoimmune cytopenias.
    D'arena G; Scalzulli PR; Nobile M; Dell'olio M; Rossi G; Cascavilla N
    Am J Hematol; 2008 Aug; 83(8):686-7. PubMed ID: 18508322
    [No Abstract]   [Full Text] [Related]  

  • 36. Rituximab in the treatment of autoimmune haematological disorders.
    Garvey B
    Br J Haematol; 2008 Apr; 141(2):149-69. PubMed ID: 18318765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Rituximab: a new therapeutic arm in refractory rheumatoid arthritis: about one case].
    Abdelmoula LC; Testouri N; Ben Hadj Yahia C; Tekaya R; Ben M'barek R; Chaabouni L; Zouari R
    Tunis Med; 2008 Sep; 86(9):841-2. PubMed ID: 19472790
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of rituximab in Felty's syndrome.
    Lekharaju V; Chattopadhyay C
    Ann Rheum Dis; 2008 Sep; 67(9):1352. PubMed ID: 18697782
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical improvement in antiphospholipid syndrome after rituximab therapy.
    Adamson R; Sangle S; Kaul A; Hughes GR; D'Cruz DP
    J Clin Rheumatol; 2008 Dec; 14(6):359-60. PubMed ID: 19033874
    [No Abstract]   [Full Text] [Related]  

  • 40. [Administration of rituximab in rheumatoid arthritis from the position of evidence-based medicine].
    Nasonov EL
    Ter Arkh; 2007; 79(12):76-82. PubMed ID: 18220039
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.